Diffuse Large B-Cell Lymphoma (DLBCL) — Deal Benchmarks & Valuation
Market Analysis
Diffuse Large B-Cell Lymphoma (DLBCL) is one of the most actively transacted indications in oncology licensing. Phase 1 deals for diffuse large b-cell lymphoma (dlbcl) carry a median total deal value of $1.0B, with upfront payments ranging from $48M to $159M. The recommended deal structure allocates approximately 10% to upfront payments and 90% to milestones.
Milestone structures for diffuse large b-cell lymphoma (dlbcl) deals allocate $365M to development milestones, $320M to regulatory milestones, and $228M to commercial milestones. Royalty rates range from 8.9% to 15.7% at the base tier, with tiered escalation reaching 12.9%-19.7% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for diffuse large b-cell lymphoma (dlbcl) licensing?
What royalty rates are standard for diffuse large b-cell lymphoma (dlbcl) deals?
How are diffuse large b-cell lymphoma (dlbcl) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.